Format

Send to

Choose Destination
Curr Opin Pediatr. 2010 Feb;22(1):2-11. doi: 10.1097/MOP.0b013e3283350d3e.

Immunotherapy of childhood cancer: from biologic understanding to clinical application.

Author information

1
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room #1-3750, 9000 Rockville Pike, MSC 1104, Bethesda, MD 20892-1104, USA. waynea@mail.nih.gov

Abstract

PURPOSE OF REVIEW:

Most children with cancer can be cured with combination regimens of chemotherapy, radiation, surgery, or all. However, standard therapies are toxic to normal tissues, cancer cells commonly develop resistance to chemotherapy, and relapsed malignancy is a leading cause of mortality in pediatrics. Elucidation of the principles of the normal immune response and tumor biology, coupled with technological developments, have led to important advances in the field of cancer immunotherapy. This review summarizes the biologic basis of cancer immunotherapy and highlights recent examples of progress in the application of novel humoral and cellular immunotherapies to children and adolescents with malignancy.

RECENT FINDINGS:

Clinical trials of immunotherapy for pediatric cancer have recently been initiated. To date, most immune-based therapies have been well tolerated and some have shown clinically significant activity against specific refractory high-risk malignancies.

SUMMARY:

Recent clinical trial results provide proof-of-principle that cancer immunotherapy has the capacity to overcome chemotherapy resistance without the usual toxicities associated with cytotoxic regimens. Immunotherapy holds promise in the treatment of children and adolescents with cancer and has the potential to improve both survival and quality of life.

PMID:
19952749
PMCID:
PMC2845444
DOI:
10.1097/MOP.0b013e3283350d3e
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center